Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Link opens in a new tab
Search content at Icahn School of Medicine at Mount Sinai
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Tralokinumab for the Treatment of Atopic Dermatitis
Egídio Freitas
,
Emma Guttman-Yassky
, Tiago Torres
Brain-Body Center
Center for Inborn Errors of Immunity
Friedman Brain Institute
Graduate School of Biomedical Sciences
Icahn School of Medicine at Mount Sinai
Marc and Jennifer Lipschultz Precision Immunology Institute
Mount Sinai Academy of Physician-Scientists
Waldman Department of Dermatology
Research output
:
Contribution to journal
›
Review article
›
peer-review
22
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Tralokinumab for the Treatment of Atopic Dermatitis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Atopic Dermatitis
100%
Tralokinumab
100%
Interleukin-13 (IL-13)
37%
Moderate-to-severe Atopic Dermatitis
25%
Immunosuppressive Therapy
12%
Inflammation
12%
Placebo
12%
Environmental Determinants
12%
Tolerability
12%
Monotherapy
12%
Phase I Trial
12%
Epidermal Barrier Dysfunction
12%
Inflammatory Skin Diseases
12%
Dosing Regimen
12%
Dysbiosis
12%
Economic Impact
12%
Genetic Determinants
12%
Multifactorial Disease
12%
Social Impact
12%
Phase IIb Clinical Trial
12%
Immune Dysregulation
12%
Every 2 weeks
12%
Topical Corticosteroids
12%
Pharmacology, Toxicology and Pharmaceutical Science
Tralokinumab
100%
Atopic Dermatitis
100%
Interleukin 13
30%
Clinical Trial
20%
Pathogenesis
20%
Inflammation
10%
Monotherapy
10%
Cytokine
10%
Pathophysiology
10%
Topical Corticosteroid
10%
Tolerability
10%
Placebo
10%
Skin Disease
10%
Dysbiosis
10%
Immune Dysregulation
10%
Diseases
10%